next generation
of eye care
potential
of effective
eye care
Want to get
the latest news
from EYE-GO?
Discover the
next generation
of eye care
Learn more
Unlock
the potential of
effective eye-care
Want to get
the latest news
from EYE-GO?
MistGo™
A game changing
experience
- Best eye treatment
- Easy to use
- High comfort
- Right delivery
- Right dose
- Every time
MistGo™ is a truly revolutionary ophthalmic
drug administration system. It is the first
eye care technology to consistently secure the right dose and the right delivery into the cornea of the eye for full exploitation of the ocular drug and optimal treatment effect.
On top, MistGo™ is extremely easy and
comfortable to use whether you are young or senior, at home or on the go. MistGo™ creates an exceptional experience that motivates people with an eye disease to complete their treatment.
Higher patient compliance translates into
healthier eyes and higher life quality.
Leading ophthalmologist and frontrunning
industry players have already named
MistGo™ a true ”game changer” in eye care.
MistGo ™
A game changing experience
- Best eye treatment
- Easy to use
- High comfort
- Right delivery
- Right dose
- Every time
Conventional eye drop bottles are inaccurate, ineffective and inconvenient. People suffering from severe, chronic eye conditions have for too long been forced to accept an unsatisfactory treatment paradigm. That is why we invented MistGo™.
MistGo™ is a truly revolutionary ophthalmic drug delivery system. It is the first eye care technology to consistently secure the right dose and the right delivery into the cornea of the eye for full exploitation of the ocular drug and optimal treatment effect. On top, MistGo™ is extremely easy and comfortable to use whether you are young or senior, at home or on the go.
MistGo™ creates an exceptional experience that motivates people with an eye disease to complete their treatment. Higher patient compliance translates into healthier eyes and higher life quality.
This superior performing technology is compatible with any ocular liquid, also preservative free that can be atomized. Leading ophthalmologist and frontrunning industry players have already named MistGo™ a true “game changer” in eye care.
MistGo
A game changing experience
- Easy to use
- High comfort
- Right delivery
- Right dose
- Every time
MistGo
A game changing experience
- Easy to use
- High comfort
- Right delivery
- Right dose
- Every time
Conventional eye drop bottles are inaccurate, ineffective and inconvenient. People suffering from severe, chronic eye conditions have for too long been forced to accept an unsatisfactory treatment paradigm. That is why we invented MistGo.
MistGo is a truly revolutionary ophthalmic drug administration system. It is the first eye care technology to consistently secure the right dose and the right delivery into the cornea of the eye for full exploitation of the drug and optimal treatment effect. On top, MistGo is extremely easy and comfortable to use whether you are young or senior, at home or on the go.
MistGo creates an exceptional experience that motivates people with an eye disease to complete their treatment. Higher patient compliance translates into improved eye health and life quality.
This superior performing technology is compatible with any ocular liquid, also preservative free that can be atomized. Leading ophthalmologist and frontrunning industry players have already named MistGo “a true game changer in eye care”.
Features
Eye care redefined
Features
Eye care redefined
Unique dose control
A high precision micro pump consistently meter a dose of only 6µl matching the optimal absorption capacity of the cornea and causing no excess liquid to irritate the skin.
Eye aiming interface
An eye aiming interface makes it easy to accurately and precisely instill the mist into the cornea without having to tilt the head in an unnatural position or to accidentally touch the eye with the device.
Gentle mist
The internal geometry of the nozzle is optimized to vaporize the liquid into a fine mist, which feels comfortable and soothing in the eye compared to a single, dense drop.
Ergonomic activation
A two-step intuitive activation procedure is designed to enable users with reduced strength in their hands to easily load and release the mist. This is particularly an advantage to seniors and children.
Instant dose release
Mechanically compressed air is used to propel and gently deliver the complete dose into the cornea, before the eye can even make a blink.
Long durability
An airtight cartridge contains the preservative free liquid to ensure its durability for minimum 6 months from the moment the device has been put into use. A smart indicator on the back of the device shows the level of liquid left, so you know when it is time to restock.
Opportunity
Make a sustainable impact
Opportunity
Make a sustainable impact
MistGo™ targets people of all ages suffering from severe and chronic eye conditions such as dry eye disease (DED), glaucoma and allergies. When left untreated or not treated correctly, these eye conditions all result in deteriorating eye health, worst case in blindness, and reduced life quality for the individual. This again bears significant costs to health economies and society at large.
MistGo™ offers people dependent on eye medication an easy way to treat their eye condition optimallly for best therapeutic effect. The effectiveness of MistGo™ even makes it cost competitive globally to the conventional eye drop bottle, and it allows the ophthalmic industry to optimize the level of active ingredients and introduce novel ocular medication for entirely new treatment possibilities. That is good news for the individual, for society and for business.
Nordic design
Simple. Basic.
Functional.
With our base in Denmark, we have been inspired by Nordic design principles in the look and feel of MistGo™. The design is simple, basic and functional making it a timeless favorite, easy to bring or use at home.
When it comes to color, print and logo options to fit different markets and users, the sky is the limit.
Nordic design
Simple. Basic.
Functional.
With our base in Denmark, we have been inspired by Nordic design principles in the look and feel of MistGo™. The design is simple, basic and functional making it a timeless favorite, easy to bring and use on the go or at home.
When it comes to color, print and logo options to fit different markets and user segments, the sky is the limit.
Sustainability
There is no planet B
Sustainability
There is
no planet B
At EYE-GO, we care for the planet and the people living on it. By enhancing the lives of people suffering from chronic eye conditions, we also improve the resource efficiency of ocular drug production. When applying MistGo™ as your ophthalmic drug delivery system, no liquid is wasted meaning less carbon emission per treatment to the benefit of the environment.
All components inside MistGo™ is made of recyclable materials. Under current regulations, we are unfortunately not able to exploit the opportunity to recycle the components. In the meantime, it is worth noting that the same amount of recyclable plastic is used per treatment with MistGo™ as with conventional drop bottles for eye care.
About EYE-GO
We shape the future of eye care. Today
About EYE-GO
We shape the future of eye care. Today
EYE-GO is a Danish-based MedTech start-up developing disruptive eye care technologies that improve the quality of life of people around the world suffering from severe and chronic eye conditions, such as dry eye disease (DED), glaucoma and allergies.
At EYE-GO, we work with some of the most esteemed experts and research institutions in the Scandinavian ophthalmic space. Our own team has extensive experience with customer centric product design and with bringing products from idea to market in the fastest and most efficient way. The board of directors, comprising strong business leaders and professional investors, contribute with many years of MedTech and venture capital experience.
EYE-GO A/S was established in 2015 and has already attracted significant funding. The circle of owners includes business angles and Maj Invest. Recently also Vækstfonden and Innovationsfonden, both owned by the Danish state, have supported EYE-GO financially.
Meet the team
Meet the team
Meet the board
of directors
Subscribe
Stay up
to date
Get the news on important developments at EYE-GO.
Subscribe now to our news alert.
Subscribe
Stay up to date
Get the news on important developments at EYE-GO.
Subscribe now to our news alert.
News
Latest news
News
Latest news
December 14th 2020.
Global press release
Disrupting eye care
Danish MedTech start-up disrupts the global market for eye care: Many challenges are associated with the conventional eye drop bottle. The global ophthalmic industry has long pushed for a way to better deliver medication to the eye. Now, the Danish-based MedTech start-up, EYE-GO, has the solution that can improve the lives of millions of people globally suffering from dry eyes and other chronic eye conditions. Leading ophthalmologists and frontrunning international players in the industry have already named it “a true game-changer in eye care”. The Danish state participated in the latest investment round.
EYE-GO has developed a truly revolutionary medical device for ophthalmic drug administration. This system is the first to consistently secure the right dose and the right delivery into the cornea of the eye so that people with severe and chronic eye conditions can benefit from the full effect of the ocular medication for improved eye health.
Henrik Nagel, CEO of EYE-GO elaborates: “One of the disruptive features of our technology is a high precision micro pump that releases a gentle mist of only 6µl (microliters), which matches the optimal absorption capacity of the cornea. In comparison, a dense drop from an eye drop bottle is between 30-60µl (microliters), which is a significant waste of resources as it cannot be absorbed in the cornea, and also risks irritating the skin around the eyes.”
The effectiveness of EYE-GO’s advanced technology makes it cost-competitive globally to the conventional eye drop bottle. It further allows the global ophthalmic industry to optimize the level of active ingredients and introduce innovative ocular medication for entirely new treatment possibilities. That is good news for patients, and for business.
Another revolutionary aspect of EYE-GO’s ocular drug delivery system is its ease of use.
Henrik explains: “We wanted to create an exceptional user experience, at the same time as delivering the best therapeutic treatment effect for the eye. The result is a system that is extremely easy and comfortable to use – whether you are young or senior, and whether you are at home or on the go. People with eye disease are simply much more inclined to complete their treatment when it can be done in a convenient, comfortable, and hassle-free way. And that translates directly into a reduced risk of blindness, improved eye health, and quality of life.”
Chairman of the board, Christian Stig Møller concludes: “We are very excited about the future. From the beginning, there has been an overwhelming interest in EYE-GO, and we are far in the dialogue with several interested pharma partners. We are also in the very fortunate position that all funding is in place to finalize the fully functional prototype that is reproducible in large numbers. That will take us from proof of technology to proof of concept.” Today, the circle of owners of EYE-GO includes business angles, Maj Invest, and as of this fall also Vækstfonden and Innovationsfonden, both owned by the Danish state.
December 2020
New funding secured
EYE-GO is excited to announce that we have raised more than USD 1 million in a new investment round. The investment has been secured with the participation of all current shareholders that comprise business angles and Maj Invest, but also from Vækstfonden and Innovationsfonden – both owned by the Danish state.
This capital injection enables us to produce our first fully functional prototype that is reproduceable in large numbers, thus moving us from proof of technology to proof of concept.
November 2020
New RA & QA Director on board
Our team is growing again. To secure a strategic approach to RA and QA as well as handle the dialogue with relevant regulatory bodies going forward, Sten Elkjær Andersen will join our team as Director of RA & QA also as of November 1st.
Sten has worked within the medico industry his entire professional career amongst others as Director of RA & QA at Ambu A/S. With Sten on board we are equipped best possible to continue to comply with and develop in line with regulatory requirements.
October 2018
New Chairman and CEO
In an effort to secure greater strategic focus and even better execution of the strategy, it has been decided to make changes in key organizational positions at EYE-GO. As of October 2018, chairman Jesper Boysen and board member Henrik E. Wulff will step out of the board. Instead former board member Christian Stig Møller has been constituted as new chairman.
At the same time, the new board of directors has decided to appoint Henrik Nagel as new CEO of EYE-GO. Henrik comes with more than 25 years of international management experience from world-leading tech companies mainly within life science. He is the perfect candidate to secure the future continued success of EYE-GO.
October 2020
Our team is growing
To further strengthen our commercial muscle and accelerate activities even further Louise von Haffner will join our team as Director of Business Development as of October 1st. With her strong track record of translating tech solutions into compelling value propositions and of bringing wining go2market strategies to life, we are certain Louise will be a great asset to our team.
At the same time we staff-up in the area of RA and QA. To secure a strategic approach to RA and QA as well as handle the dialogue with relevant regulatory bodies going forward, Sten Elkjær Andersen will join our team as Director of RA & QA also as of October 1st. Sten has worked within the medico industry his entire professional career amongst others as Director of RA & QA at Ambu A/S. With Sten on board we are equipped best possible to continue to comply with and develop in line with regulatory requirements